Bristol-Myers Squibb Co. (BMY)

46.98
NYSE : Health Technology
Prev Close 45.75
Day Low/High 45.78 / 47.06
52 Wk Low/High 42.48 / 63.69
Avg Volume 12.92M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 74.84B
EPS 3.00
P/E Ratio 12.04
Div & Yield 1.64 (3.57%)

Latest News

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

PTC Therapeutics Expands Presence In New Jersey By Securing State-of-the-Art Biologics Facility

PTC Therapeutics Expands Presence In New Jersey By Securing State-of-the-Art Biologics Facility

- Facility will support gene therapy production and continued development of pipeline of investigational medicines -

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

Jim Cramer: 7 Sectors You Can Buy as the Trade War Continues

These stocks and sectors are safe havens, and may even be opportunities.

BMY: Insiders Vs. Shorts

BMY: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Bristol-Myers Squibb Co. is the #186 most shorted of the S&P 500 components, based on 4.20 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo® (nivolumab) For The Treatment Of Patients With Untreated Advanced Melanoma

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo® (nivolumab) For The Treatment Of Patients With Untreated Advanced Melanoma

SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.

Bristol-Myers Squibb Announces European Commission Approval Of Pending Acquisition Of Celgene

Bristol-Myers Squibb Announces European Commission Approval Of Pending Acquisition Of Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb's pending acquisition of Celgene Corporation (NASDAQ:CELG).

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti (elotuzumab) plus...

Trade War Taking a Toll: Cramer's 'Mad Money' Recap (Thursday 7/25/19)

Trade War Taking a Toll: Cramer's 'Mad Money' Recap (Thursday 7/25/19)

The non-consumer economy is just plain worrisome, says Jim Cramer, and our industrials are warning of weakness related to the trade war with China.

Stocks End Lower as Earnings Disappoint Wall Street

Stocks End Lower as Earnings Disappoint Wall Street

Stocks finish down Thursday, one day after the Nasdaq and the S&P 500 closed at record highs, as investors retreat from disappointing earnings reports.

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Jim Cramer: Add 'Better Than Feared' to Your Investing Lexicon

Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.

Bristol-Myers Tops Q2 Profit Forecast, Boosts Guidance as Eliquis Impresses

Bristol-Myers Tops Q2 Profit Forecast, Boosts Guidance as Eliquis Impresses

Bristol-Myers Squibb posts stronger-than-expected second-quarter earnings and boost its full-year profit forecast while adding that its $74 billion acquisition of Celgene would likely close in early 2020.

Amazon, Alphabet, 3M and More - Earnings to Watch

Amazon, Alphabet, 3M and More - Earnings to Watch

Here are the key earnings on Thursday, July 25.

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

SOX It to Me, Military Mischief in Asia, and Awaiting Amazon: Market Recon

And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2019, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab) and a robust operating performance across the portfolio.

Tesla, Facebook, Amazon, Alphabet and ECB - 5 Things You Must Know

Tesla, Facebook, Amazon, Alphabet and ECB - 5 Things You Must Know

U.S. stock futures are mixed on Thursday, a day after the S&P 500 and Nasdaq reached all-time highs, and ahead of the busiest day so far of the quarterly earnings season; Tesla falls sharply after posting a wider-than-expected loss and announcing its chief technology officer would be stepping down; Facebook's earnings top forecasts as monthly-active users rise; Amazon and Alphabet report earnings Thursday.

Bristol-Myers Squibb Provides Update On Part 2 Of CheckMate -227

Bristol-Myers Squibb Provides Update On Part 2 Of CheckMate -227

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 2 of the Phase 3 CheckMate -227 trial did not meet the primary endpoint of overall survival (OS) with Opdivo ® (nivolumab) plus chemotherapy versus chemotherapy in patients with first-line...

Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint Of Overall Survival

Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint Of Overall Survival

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo ® (nivolumab) plus low-dose Yervoy ® (ipilimumab) met the co-primary endpoint of overall survival (OS), demonstrating a superior...

Earnings Ahead: Cramer's 'Mad Money' Recap (Friday 7/19/19)

Earnings Ahead: Cramer's 'Mad Money' Recap (Friday 7/19/19)

Jim Cramer says we're heading into the busiest week of earnings season. He's got your game plan, but says it might be a good time to take your summer vacation.

Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Into A Clinical Collaboration Agreement To Investigate Stivarga® (regorafenib) And Opdivo® (nivolumab) As Combination Therapy In Patients With Metastatic Colorectal Cancer

Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Into A Clinical Collaboration Agreement To Investigate Stivarga® (regorafenib) And Opdivo® (nivolumab) As Combination Therapy In Patients With Metastatic Colorectal Cancer

- Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer

Jim Cramer: Big Tech in Washington Will Mean an EPS Hit

Jim Cramer: Big Tech in Washington Will Mean an EPS Hit

Breaking down the impact on Facebook, Alphabet and Amazon of congressional hearings.

Don't Trade, Invest: Cramer's 'Mad Money' Recap (Monday 7/15/19)

Don't Trade, Invest: Cramer's 'Mad Money' Recap (Monday 7/15/19)

Jim Cramer says don't trade earnings season, invest in it -- and invest the time needed to be a smart, successful investor.

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Jim Cramer weighs in on Bristol-Myers Squibb, Eli Lily, DuPont, Marvell Technology, General Motors, Kraft Heinz, Maxar Technologies, and more.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

TheStreet Quant Rating: C+ (Hold)